FDA Grants Priority Review for Johnson & Johnson's Expanded Use Application for Rybrevant Faspro
Johnson & Johnson (JNJ) has received priority review from the FDA for its application to expand the U.S. label of its cancer therapy, Rybrevant Faspro, developed in partnership with Halozyme Therapeutics (HALO). The proposed expansion targets a specific type of head and neck cancer. This regulatory development highlights J&J's ongoing efforts to broaden the therapeutic applications of Rybrevant Faspro. Priority review status typically expedites the FDA’s evaluation process, potentially leading to faster approval decisions compared to standard timelines.
